MPPT – Frontiers in Medicine

New MPPT clinical study:
100% closure rate of pressure ulcers

Download Publication

Download Publication

Download Publication

Slider-web-60%

MPPT removes wound infections 60%
quicker than antibiotics and antiseptics.

Effective on resistant infections and does not contribute to AMR.

Effective on resistant infections and does not contribute to AMR.

Effective on resistant infections and does not contribute to AMR.

Slider-web-passive-immunotherapy

Passive Immunotherapy

acting via the skin and wound microbiome without the use of antimicrobials.

acting via the skin and wound microbiome without the use of antimicrobials.

acting via the skin and wound microbiome without the use of antimicrobials.

Slider-web-pain-etc

Amicapsil and Amicapsil-SCI

Effective wound treatment in immunocompetent and immunocompromised persons

Effective wound treatment in immunocompetent and immunocompromised persons

Effective wound treatment in immunocompetent and immunocompromised persons

Slider-web-1

“Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic.” Patient ST

“Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

“Where I have used Aprobaxil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

Slider-web-1 – NH

“Amicapsil changed my life.”

“From 4 weeks of absolute hell – to being pain-free, getting a full night’s sleep and back to normal at work.”

“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”

“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”

NH ( patient)

NH ( patient)

NH ( patient)

Slider-web-15

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Slider-web-hypoallergenic

Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

Slider-web-FDA

FDA concluded in 2022:

Standard wound products, including antimicrobials, are ineffective.

Standard wound products, including antimicrobials, are ineffective.

Standard wound products, including antimicrobials, are ineffective.

US FDA 2016

US FDA 2016

Verma et al. (2022)

Slider-web-AMR

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.

Slider-web-AMR

Antimicrobials are environmentally unsustainable and contribute to climate change.
MPPT removes infections without the use of antimicrobials.

Slider-web-No-brainer

“For me, this Amicapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

VH (patient)

VH (patient)

Slider-web-Pollution

MPPT is environmentally sustainable:
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.

Can MPPT benefit acute and chronic wounds, e.g. post-surgical wounds, trauma wounds and burns?

Yes, MPPT can benefit all types of non-sterile wounds that are to close by secondary or tertiary intention; in other words any wound that cannot be sutured or needs to clear up and start granulating before suturing can be assisted by MPPT. MPPT can be used on low to highly exuding wounds, as well as wounds with necrosis and infection.

The majority of trauma wounds and dehisced (burst open) surgical wounds cannot be sutured and can highly benefit from Acapsil application.

Related Posts

January 5’th, 2024 – MPPT clinical study published in Frontiers in Medicine

The clinical trial “Stable closure of acute and chronic wounds and pressure ulcers and control of draining fistulas from osteomyelitis

October 8’th to 11’th, 2023 – Spinal Injuries Association presents poster on Amicapsil at the annual ISCoS meeting.

Damian Smith from SIA (Spinal Injuries Association) will present the results of a survey in the SCI-community on the experiences